Scientists at La Jolla Institute for Immunology (LJI) have found a potential new target for treating Parkinson's disease.

From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, scientists have been able to identify patterns of neurodegeneration and create ...

The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of ...

The work, published in NPJ Parkinson's Disease ... it has been possible to relate the degree of progression of the disease – the five stages of clinical symptoms – to quantitative changes in brain ...

A form of Parkinson's disease caused by mutations in a gene known as PINK1 has long been labeled rare. But our research shows ...

The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in ...

By combining advanced blood analysis with artificial intelligence, the test is able to identify early signs of Parkinson’s disease in individuals who have not yet shown clinical symptoms ...

Berlin, Germany, and Research Triangle Park, N.C., USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Not intended for UK MediaRegenerative Medicine ...

Researchers at Shanghai Huashan Hospital have identified a novel therapeutic target that could lead to the world's first ...

In a recent study, talk therapy in Parkinson’s disease led to significant improvement in patients' well-being, problems/symptoms, and functioning.

The FDA has approved an adaptive deep brain stimulation (aDBS) treatment for people with with Parkinson’s disease, making this groundbreaking technology available to people nationwide.